Tukki Sarkar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tukki Sarkar has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Sai Balaji Andugulapati
Academy of Scientific and Innovative Research (AcSIR)
5 shared publications - Bathini Nagendra Babu
Department of Fluoro-Agrochemicals CSIR-Indian Institute of Chemical Technology Hyderabad 500007, Telangana India
4 shared publications - Akhtar Hussain
Department of Chemistry, Handique Girls’ College, Guwahati 781001, Assam, India
3 shared publications Jyotirmoy Dutta
Handique Girls’ College Panbazar
3 shared publications- Samya Banerjee
Indian Institute of Technology (BHU)
3 shared publications - Swati Biswas
Nanomedicine Research Laboratory, Department of Pharmacy, Birla Institute of Technology & Science-Pilani, Hyderabad Campus, Medchal, Hyderabad, 500078, Telangana, India
3 shared publications
Latest Publications
- 1 October 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (20) , 23898-23914
Direct S,S Coordination Suppresses Pt(II)-Thiol Reactivity to Mitigate Nephrotoxicity and Enable Chemo-Photodynamic Therapy against Metastatic Triple-Negative Breast Cancer
Platinum chemotherapy is limited by the thiol reactivity of Pt(II), which promotes interactions with sulfur-containing biomolecules, causing nephrotoxicity and drug deactivation while providing limited efficacy against metastatic disease. Here, we show that direct S,S coordination suppresses Pt(II)-thiol reactivity, mitigating nephrotoxicity while enabling chemo-photodynamic therapy. Three Pt(II) complexes (Pt1−Pt3) containing a dithiolene ligand were designed to pre-satisfy the sulfur affinity of Pt(II). The lead complex, Pt3, resists glutathione binding, exhibits cytotoxicity toward 4T1 triple-negative breast cancer cells (IC50 = 6.05 μM), and shows a 2.6-fold enhancement under 660 nm red-light irradiation (IC50 = 2.29 μM) through singlet oxygen-mediated apoptosis, while remaining minimally toxic to HEK-293 normal kidney cells (IC50 > 100 μM). In an orthotopic 4T1 tumor model, Pt3 demonstrated potent in vivo antitumor activity with reduced nephrotoxicity and suppressed lung metastasis relative to cisplatin and oxaliplatin, establishing direct S,S coordination as a medicinal design strategy for safer Pt(II) chemotherapeutics.
- 1 October 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (20) , 23898-23914
Direct S,S Coordination Suppresses Pt(II)-Thiol Reactivity to Mitigate Nephrotoxicity and Enable Chemo-Photodynamic Therapy against Metastatic Triple-Negative Breast Cancer
Platinum chemotherapy is limited by the thiol reactivity of Pt(II), which promotes interactions with sulfur-containing biomolecules, causing nephrotoxicity and drug deactivation while providing limited efficacy against metastatic disease. Here, we show that direct S,S coordination suppresses Pt(II)-thiol reactivity, mitigating nephrotoxicity while enabling chemo-photodynamic therapy. Three Pt(II) complexes (Pt1−Pt3) containing a dithiolene ligand were designed to pre-satisfy the sulfur affinity of Pt(II). The lead complex, Pt3, resists glutathione binding, exhibits cytotoxicity toward 4T1 triple-negative breast cancer cells (IC50 = 6.05 μM), and shows a 2.6-fold enhancement under 660 nm red-light irradiation (IC50 = 2.29 μM) through singlet oxygen-mediated apoptosis, while remaining minimally toxic to HEK-293 normal kidney cells (IC50 > 100 μM). In an orthotopic 4T1 tumor model, Pt3 demonstrated potent in vivo antitumor activity with reduced nephrotoxicity and suppressed lung metastasis relative to cisplatin and oxaliplatin, establishing direct S,S coordination as a medicinal design strategy for safer Pt(II) chemotherapeutics.
- 3 July 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (14) , 16819-16833
Red-Light-Triggered In Vitro and In Vivo Photocatalytic Cancer Therapy with Polypyridyl Os(II) Photocatalysts
Herein, we have designed, synthesized, and characterized four Os(II) photocatalysts, viz, [Os(phtpy)2](PF6)2 (Os1), [Os(CF3-phtpy)2](PF6)2 (Os2), [Os(OH-phtpy)2](PF6)2 (Os3), and [Os(quinoline-tpy)2](PF6)2 (Os4). Os1-Os4 exhibited high absorption in the red region, making them suitable candidates for red-light-triggered catalytic anticancer applications. SC-XRD analysis of Os3 and Os4 confirmed the distorted octahedral geometry of the OsIIN6 core. Theoretical studies provided insight into the electronic structure and excited-state properties of Os1-Os4. Under red light (633 nm, 27 mW cm-2), Os1-Os4 exhibited selective NADH oxidation with TOF up to 13.70 h-1 and efficient ROS generation (Φ1O2 up to 0.25). As a consequence, Os1-Os4 exhibited pronounced red-light-triggered anticancer activity against MDA-MB-231, MCF-7, and HeLa cells. Moreover, in vivo studies using an orthotopic mouse model revealed that Os4 significantly reduced tumor volume in a dose-dependent manner upon 650 nm laser (90 J cm-2) exposure by upregulating Bax and downregulating Bcl-2, while it had good in vivo biosafety in the dark.
- 3 July 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (14) , 16819-16833
Red-Light-Triggered In Vitro and In Vivo Photocatalytic Cancer Therapy with Polypyridyl Os(II) Photocatalysts
Herein, we have designed, synthesized, and characterized four Os(II) photocatalysts, viz, [Os(phtpy)2](PF6)2 (Os1), [Os(CF3-phtpy)2](PF6)2 (Os2), [Os(OH-phtpy)2](PF6)2 (Os3), and [Os(quinoline-tpy)2](PF6)2 (Os4). Os1-Os4 exhibited high absorption in the red region, making them suitable candidates for red-light-triggered catalytic anticancer applications. SC-XRD analysis of Os3 and Os4 confirmed the distorted octahedral geometry of the OsIIN6 core. Theoretical studies provided insight into the electronic structure and excited-state properties of Os1-Os4. Under red light (633 nm, 27 mW cm-2), Os1-Os4 exhibited selective NADH oxidation with TOF up to 13.70 h-1 and efficient ROS generation (Φ1O2 up to 0.25). As a consequence, Os1-Os4 exhibited pronounced red-light-triggered anticancer activity against MDA-MB-231, MCF-7, and HeLa cells. Moreover, in vivo studies using an orthotopic mouse model revealed that Os4 significantly reduced tumor volume in a dose-dependent manner upon 650 nm laser (90 J cm-2) exposure by upregulating Bax and downregulating Bcl-2, while it had good in vivo biosafety in the dark.
- 22 June 2026
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 17 (7) , 1636-1646
Ligand-Engineered Cu(II) Complexes Suppress Stemness and Drug Resistance in Triple-Negative Breast Cancer
Triple-negative breast cancer (TNBC) is an aggressive malignancy characterized by cancer stem cell (CSC) enrichment and multidrug resistance. Here, we report a series of Cu-(II) complexes (Cu1-Cu4) designed to investigate the impact of ligand engineering on anticancer activity. The lead complexes, Cu3 and Cu4, incorporating an anthracene-appended imidazophenanthroline scaffold, exhibit submicromolar antiproliferative activity against TNBC cell lines, outperforming oxaliplatin under comparable conditions. Mechanistic studies demonstrate that Cu3 and Cu4 induce cell-cycle arrest and apoptosis while suppressing epithelial-mesenchymal transition (EMT) and tumor cell migration. Notably, both complexes significantly attenuate 3D tumor spheroid formation and reduce CSC-associated markers, including the CD44high/CD24low subpopulation, indicating a reduction in CSC population and spheroid-forming capacity. Furthermore, Cu3 and Cu4 enhance intracellular retention of doxorubicin by downregulating ABC transporter expression, highlighting their ability to modulate drug-resistance mechanisms. These findings identify ligand-engineered Cu-(II) complexes as promising scaffolds for reducing CSC-associated features and overcoming chemoresistance in TNBC.
- 22 June 2026
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 17 (7) , 1636-1646
Ligand-Engineered Cu(II) Complexes Suppress Stemness and Drug Resistance in Triple-Negative Breast Cancer
Triple-negative breast cancer (TNBC) is an aggressive malignancy characterized by cancer stem cell (CSC) enrichment and multidrug resistance. Here, we report a series of Cu-(II) complexes (Cu1-Cu4) designed to investigate the impact of ligand engineering on anticancer activity. The lead complexes, Cu3 and Cu4, incorporating an anthracene-appended imidazophenanthroline scaffold, exhibit submicromolar antiproliferative activity against TNBC cell lines, outperforming oxaliplatin under comparable conditions. Mechanistic studies demonstrate that Cu3 and Cu4 induce cell-cycle arrest and apoptosis while suppressing epithelial-mesenchymal transition (EMT) and tumor cell migration. Notably, both complexes significantly attenuate 3D tumor spheroid formation and reduce CSC-associated markers, including the CD44high/CD24low subpopulation, indicating a reduction in CSC population and spheroid-forming capacity. Furthermore, Cu3 and Cu4 enhance intracellular retention of doxorubicin by downregulating ABC transporter expression, highlighting their ability to modulate drug-resistance mechanisms. These findings identify ligand-engineered Cu-(II) complexes as promising scaffolds for reducing CSC-associated features and overcoming chemoresistance in TNBC.
- 1 January 2026
- Published by Royal Society of Chemistry (RSC) in Dalton Transactions
Ferrocene is not always better: phenyl substitution outperforms ferrocenyl substitution in Cu( ii ) terpyridine–quinolone anticancer complexes
Phenyl substitution outperforms ferrocenyl substitution in Cu( ii ) terpyridine–quinolone anticancer complexes, revealing an unexpected and context-dependent structure–activity relationship for ferrocene incorporation.
- 1 January 2026
- Published by Royal Society of Chemistry (RSC) in Dalton Transactions
Ferrocene is not always better: phenyl substitution outperforms ferrocenyl substitution in Cu( ii ) terpyridine–quinolone anticancer complexes
Phenyl substitution outperforms ferrocenyl substitution in Cu( ii ) terpyridine–quinolone anticancer complexes, revealing an unexpected and context-dependent structure–activity relationship for ferrocene incorporation.
- Open Access
- 22 September 2025
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 15 (42) , 35445-35459
Pyrido-indole-one hybrids as potential anticancer agents against breast carcinoma: development of Ru( ii )-catalyzed annulation of indole-2-carboxamides, biological screening and molecular docking studies
Ru( ii )-catalyzed synthesis of 1 H -pyrido[3,4- b ]indol-1-one hybrids via annulation of indole amides with ynones yielded compound 9c, showing selective cytotoxicity toward MDA-MB-231 cells and moderate EGFR affinity, indicating therapeutic promise.
- 22 September 2025
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 15 (42) , 35445-35459
Open AccessPyrido-indole-one hybrids as potential anticancer agents against breast carcinoma: development of Ru( ii )-catalyzed annulation of indole-2-carboxamides, biological screening and molecular docking studies
Ru( ii )-catalyzed synthesis of 1 H -pyrido[3,4- b ]indol-1-one hybrids via annulation of indole amides with ynones yielded compound 9c, showing selective cytotoxicity toward MDA-MB-231 cells and moderate EGFR affinity, indicating therapeutic promise.
- 11 July 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (14) , 15137-15150
Trimodal Ni(II) Complex of Natural Coumarin: Enhanced Lung Cancer Therapy through Chemo, Photodynamic, and Photothermal Approaches under Red and NIR Light
We report four square planar Ni(II) complexes [Ni(B)(L)] (S1-S4), where B is 1,10-phenanthroline (S1, S2) or dipyrido[3,2-a:2',3'-c]phenazine (S3, S4) and L is the dianionic form of catechol (S1, S3) or esculetin (S2, S4). These complexes absorb in the red and NIR region (600-850 nm) and remain stable under thermal, photo, and dark conditions. S4 showed strong phototoxicity under combined 660 and 808 nm light via singlet oxygen generation and local hyperthermia, with IC50 = 0.9 μM in A549 lung cancer cells, but negligible toxicity to HEK-293 normal kidney cells. Mechanistic studies revealed apoptosis, G2/M arrest, and ROS-mediated cell damage. Molecular docking studies showed significant interaction of S4 with HER2 and Cyclin D1 proteins, suggesting apoptosis via inhibition. To the best of our knowledge, this is the first report of a first-row transition metal complex for application in trimodal lung cancer therapy within the clinical phototherapeutic window.
- 11 July 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (14) , 15137-15150
Trimodal Ni(II) Complex of Natural Coumarin: Enhanced Lung Cancer Therapy through Chemo, Photodynamic, and Photothermal Approaches under Red and NIR Light
We report four square planar Ni(II) complexes [Ni(B)(L)] (S1-S4), where B is 1,10-phenanthroline (S1, S2) or dipyrido[3,2-a:2',3'-c]phenazine (S3, S4) and L is the dianionic form of catechol (S1, S3) or esculetin (S2, S4). These complexes absorb in the red and NIR region (600-850 nm) and remain stable under thermal, photo, and dark conditions. S4 showed strong phototoxicity under combined 660 and 808 nm light via singlet oxygen generation and local hyperthermia, with IC50 = 0.9 μM in A549 lung cancer cells, but negligible toxicity to HEK-293 normal kidney cells. Mechanistic studies revealed apoptosis, G2/M arrest, and ROS-mediated cell damage. Molecular docking studies showed significant interaction of S4 with HER2 and Cyclin D1 proteins, suggesting apoptosis via inhibition. To the best of our knowledge, this is the first report of a first-row transition metal complex for application in trimodal lung cancer therapy within the clinical phototherapeutic window.
- 14 May 2025
- Published by Royal Society of Chemistry (RSC) in Inorganic Chemistry Frontiers
- Vol. 12 (20) , 6204-6219
Four-in-one multifunctional iron(iii) complex for cancer theranostics: unique integration of targeted delivery, photodynamic therapy, and dual imaging modalities
We report Fe2 as the first complex with four distinct functions for cancer theranostics: GLUT-1 targeting, red-light PDT, optical imaging, and T1-weighted MRI. It selectively kills cancer cells, spares normal cells, and enables multimodal imaging.
- 14 May 2025
- Published by Royal Society of Chemistry (RSC) in Inorganic Chemistry Frontiers
- Vol. 12 (20) , 6204-6219
Four-in-one multifunctional iron(iii) complex for cancer theranostics: unique integration of targeted delivery, photodynamic therapy, and dual imaging modalities
We report Fe2 as the first complex with four distinct functions for cancer theranostics: GLUT-1 targeting, red-light PDT, optical imaging, and T1-weighted MRI. It selectively kills cancer cells, spares normal cells, and enables multimodal imaging.
- 21 February 2025
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 17 (9) , 13660-13675
Photostable Mn(II) Complex of Curcumin for Effective Photodynamic Therapy and Precise Three-Dimensional In Vivo Tumor Imaging
Photoactive complexes of first-row transition metals with emission properties offer a dual approach to cancer treatment, enabling precise optical tumor detection and subsequent eradication using light. We report a photostable and photoactive mixed-ligand Mn(II) complex, Mn4, featuring a naturally occurring curcumin ligand and dipyridophenazine base. Mn4 demonstrates significant visible and red light-triggered phototoxicity against cancer cells and precise tumor imaging capability in vivo. The complex exhibits an absorption band in the visible region, extending its tail into the red region, and shows excellent dark and photostability in solution. Mn4 induces significant phototoxicity against HeLa (cervical), A549 (lung), and MCF-7 (breast) cancer cells (IC50 ≈ 1.0 μM), as well as 3D multicellular tumor spheroids, under low-energy visible (400-700 nm) and red-light (660 nm). This effect is mediated by cytotoxic singlet oxygen and proceeds via an apoptotic mechanism. Importantly, Mn4 displays significantly lower toxicity toward normal HPL1D lung and HEK-293 kidney cells under similar conditions. Cellular uptake studies reveal selective accumulation of Mn4 in A549 cancer cells, with mitochondrial localization, and negligible accumulation in BEAS-2B normal lung cells. Furthermore, 3D optical tumor imaging demonstrated Mn4's selective tumor accumulation in a 4T1 breast tumor-bearing in vivo mouse model. In vivo efficacy studies using a 4T1 tumor-bearing orthotopic mouse model show that Mn4 significantly reduces tumor volume and weight in a dose-dependent manner under low-energy blue laser (450 nm) irradiation, highlighting its potential as an effective photodynamic therapy (PDT) agent. Toxicological studies confirm that Mn4 does not induce abnormal biochemical or hematological parameters in healthy mice. To our knowledge, this is the first report of a Mn(II) complex with curcumin and the first example of a metal complex with curcumin for combined in vivo PDT and noninvasive 3D optical tumor imaging, paving the way for nonmacrocyclic Mn-based cancer phototheranostics.
- 21 February 2025
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 17 (9) , 13660-13675
Photostable Mn(II) Complex of Curcumin for Effective Photodynamic Therapy and Precise Three-Dimensional In Vivo Tumor Imaging
Photoactive complexes of first-row transition metals with emission properties offer a dual approach to cancer treatment, enabling precise optical tumor detection and subsequent eradication using light. We report a photostable and photoactive mixed-ligand Mn(II) complex, Mn4, featuring a naturally occurring curcumin ligand and dipyridophenazine base. Mn4 demonstrates significant visible and red light-triggered phototoxicity against cancer cells and precise tumor imaging capability in vivo. The complex exhibits an absorption band in the visible region, extending its tail into the red region, and shows excellent dark and photostability in solution. Mn4 induces significant phototoxicity against HeLa (cervical), A549 (lung), and MCF-7 (breast) cancer cells (IC50 ≈ 1.0 μM), as well as 3D multicellular tumor spheroids, under low-energy visible (400-700 nm) and red-light (660 nm). This effect is mediated by cytotoxic singlet oxygen and proceeds via an apoptotic mechanism. Importantly, Mn4 displays significantly lower toxicity toward normal HPL1D lung and HEK-293 kidney cells under similar conditions. Cellular uptake studies reveal selective accumulation of Mn4 in A549 cancer cells, with mitochondrial localization, and negligible accumulation in BEAS-2B normal lung cells. Furthermore, 3D optical tumor imaging demonstrated Mn4's selective tumor accumulation in a 4T1 breast tumor-bearing in vivo mouse model. In vivo efficacy studies using a 4T1 tumor-bearing orthotopic mouse model show that Mn4 significantly reduces tumor volume and weight in a dose-dependent manner under low-energy blue laser (450 nm) irradiation, highlighting its potential as an effective photodynamic therapy (PDT) agent. Toxicological studies confirm that Mn4 does not induce abnormal biochemical or hematological parameters in healthy mice. To our knowledge, this is the first report of a Mn(II) complex with curcumin and the first example of a metal complex with curcumin for combined in vivo PDT and noninvasive 3D optical tumor imaging, paving the way for nonmacrocyclic Mn-based cancer phototheranostics.